Effectiveness of magnetic fields in treating fatigue in patients with multiple sclerosis.

Not Applicable

Completed

• Conditions: Multiple Sclerosis; Neurological - Multiple sclerosis; Inflammatory and Immune System - Autoimmune diseases

• Registration Number: ACTRN12618000515291
• Lead Sponsor: Hospital Universitario Virgen Macarena

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-04-09
• Study Completion: 2019-12-20
• Last Update Posted: 4 April 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

Subject with a definitive diagnosis of Relapsing-Remitting Multiple Sclerosis with a stable disease over the previous four months;
- 18 years of age or older;
- EDSS score less than or equal to 5,5;
- Cognitive capacity to complete the assessment and the treatment protocol;
- Reporting fatigue assesed with MFIS and FSS scale.

Exclusion Criteria

- Pregnancy
- No cognitive capacity to complete the assessment and the treatment protocol;
-EDSS score more than 5.5
- Use of drugs and medication specifically prescribed to decrease fatigue.
- MS relapse during treatment (defined as any change in symptoms according to
the EDSS evaluation) within the month before data collection
-Diagnosed psychiatric disorders; epilepsy; concomitant chronic disorders that may evoke fatigue, such as fibromyalgia; and possible secondary causes of fatigue.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fatigue assessed with Fatigue Severity Scale (FSS).[Before the intervention, at the end of the intervention and at 3 months after intervention.];Fatigue assessed with Modified Fatigue Impact Scale (MFIS).[Before the intervention, at the end of the intervention and at 3 months after intervention.]

Secondary Outcome Measures

Name	Time	Method
Quality of life assessed with MusiQoL. [Before the intervention, at the end of the intervention and at 3 months after intervention.];Temporal and spatial gait parameters (velocity, step-length difference, functional ambulation performance, step-time difference and cadence) assessed by GAITRite electronic walkway. This is a composite secondary outcome.[Before the intervention, at the end of the intervention and at 3 months after intervention.];Depression levels through the Beck Depression Inventory II (BDI-II).[Before the intervention, at the end of the intervention and at 3 months after intervention.]